Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review found moderate to very low-quality evidence that spironolactone, flutamide, and cyproterone acetate combined with oral contraceptives may reduce hirsutism more effectively than placebo or metformin, though results vary among other treatments.

This study used molecular docking to identify stiripentol as a potential new inhibitor of the SRD5A2 enzyme, which is targeted for treating androgen-related diseases; however, in vivo trials are needed to validate its efficacy.

This article discusses various manifestations and treatment methods for hyperandrogenism syndrome, particularly focusing on the effectiveness of systemic antiandrogenic therapy for severe or moderate hirsutism, and reports no new clinical results.

This study found that GnRH agonist treatment improved hirsutism scores more than finasteride after six months in women with idiopathic hirsutism, with both treatments causing no menstrual abnormalities or side-effects.

This trial will compare the effectiveness of spironolactone to doxycycline for treating acne in adult females, potentially offering an alternative to antibiotics and isotretinoin.

This study reports that spironolactone, a potassium-sparing diuretic with antiandrogenic activity, effectively improves hair density, reduces shedding, and stabilizes symptoms in female pattern hair loss, though symptoms often recur after discontinuation, suggesting the need for sustained therapy.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

This review updates dermatologists on both FDA-approved and off-label hormonal therapies, including combined oral contraceptives, clascoterone, and spironolactone, used for acne treatment, providing insights into emerging approaches for managing the condition.

This study suggests that spironolactone-loaded nanostructured lipid carriers could enhance follicular delivery and offer a more localized treatment for androgenic alopecia, potentially reducing systemic side effects.

This study describes a planned multicenter randomized controlled trial to assess the safety, tolerability, and pharmacokinetics of subdermal gestrinone pellets in patients with deep infiltrative endometriosis-related pelvic pain, but it does not report any findings yet.

This article argues that prolactin may have a role in sebaceous gland function and suggests it could be a potential target for treating skin conditions, but reports no new clinical findings.

This review discusses adrenal gland disease in ferrets, exploring its signs, potential contributing factors, and current treatment options, but it reports no new clinical results.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

This study found that the L457(3.43)R mutation in the human luteinizing hormone receptor increases phosphodiesterase activity, reducing hormonal response despite elevated basal cAMP levels.

This report presents a case of familial male-limited precocious puberty with a novel LHCGR gene mutation, where a boy responded well to treatment with bicalutamide and anastrozole.

In this study, cosyntropin-induced cortisol spikes did not affect hair cortisol concentration in captive grizzly bears, contrasting with stress responses observed in free-ranging bears during capture.

This study found that in dogs with post-clipping alopecia, microneedling with platelet-rich plasma may induce more rapid hair regrowth compared to microneedling alone, though results were similar by six months.

This study found no correlation between clinical signs and sex steroid levels in ferrets with hyperadrenocorticism and noted that androstenedione was elevated in many cases.

In this animal study, finasteride was found to significantly lower cortisol and increase testosterone levels in female rats, indicating its broader impact on endocrine regulation by altering adrenal and gonadal hormones.

In this study, the authors reported a case of alopecia X in a German Spitz dog and found that treatment with orchiectomy and melatonin resulted in partial hair regrowth and improved the dog's dermatological condition.

The researchers reported that finasteride was effective in controlling hormone-related dysfunction in an adult dog diagnosed with benign prostatic hyperplasia, although the condition regressed after the medication was withdrawn.

This chapter reviews the clinical features, diagnosis, treatment, and prognosis of various non-hormonal, non-infectious alopecias without providing new clinical findings.

Different types of hair loss in dogs and cats have various causes and treatments, with outcomes ranging from good to uncertain.

This article updates on the medical management of benign prostatic hyperplasia in companion animals and reports no new clinical findings; the authors discuss existing treatments.

The document concludes that various drugs for men's health issues are in development, with treatments for sexual dysfunction and prostate conditions being the most advanced.

This brief report discusses spironolactone used as a treatment for hirsutism in a hyperandrogenic woman, offering no new clinical findings and focusing on its antiandrogenic properties.

In this randomized study of male contraceptive regimens, adding finasteride did not significantly enhance spermatogenesis suppression compared to the control group.

This review discusses the use of spironolactone for common skin diseases like acne and its potential role in daily clinical practice but presents no new clinical results.